MicroRNA-485-5p inhibits glioblastoma progression by suppressing E2F transcription factor 1 under cisplatin treatment

References

• Armstrong TS, Wen PY, Gilbert MR, et al. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012;14(10):1203–1214.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Bageritz J, Puccio L, Piro RM, et al. Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ. 2014;21(6):929–940.
   PubMed Web of Science ®Google Scholar
• Bernhart E, Damm S, Heffeter P, et al. Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro Oncol. 2014;16(7):933–945.
   PubMed Web of Science ®Google Scholar
• Shen Q, Xu Z, Xu S. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer. Int J Oncol. 2020;57:967–979.
   PubMed Web of Science ®Google Scholar
• Zhai B, Chen P, Wang W, et al. An ATF(24) peptide-functionalized β-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment. Cancer Biol Med. 2020;17:676–692.
   PubMed Web of Science ®Google Scholar
• Chen H, Zheng B, Xue S, et al. Knockdown of miR-183 enhances the cisplatin-induced apoptosis in esophageal cancer through increase of FOXO1 expression. Onco Targets Ther. 2020;13:8463–8474.
   PubMed Web of Science ®Google Scholar
• Contreras-Ochoa CO, López-Arellano ME, Roblero-Bartolon G, et al. Molecular mechanisms of cell death induced in glioblastoma by experimental and antineoplastic drugs: new and old drugs induce apoptosis in glioblastoma. Hum Exp Toxicol. 2020;39(4):464–476.
   PubMed Web of Science ®Google Scholar
• Wang M, Wu Q, Fang M, et al. miR-152-3p sensitizes glioblastoma cells towards cisplatin via regulation of SOS1. Onco Targets Ther. 2019;12:9513–9525.
   PubMed Web of Science ®Google Scholar
• Kim HI, Hong SH, Ku JM, et al. Gardenia jasminoides enhances CDDP-induced apoptosis of glioblastoma cells via AKT/mTOR pathway while protecting death of astrocytes. Nutrients. 2020;12. DOI:10.3390/nu12010196.
   Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866.
   PubMed Web of Science ®Google Scholar
• Weng L, Ma J, Jia YP, et al. MiR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: involvement of GALNT4. Am J Transl Res. 2018;10:3969–3977.
   PubMed Web of Science ®Google Scholar
• Ma F, Zhang L, Ma L, et al. MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin Cancer Res. 2017;36(1):158.
   PubMedGoogle Scholar
• Li J, Song J, Guo F. miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med. 2019;43:517–524.
   PubMed Web of Science ®Google Scholar
• Shao L, He Q, Liu Y, et al. UPF1 regulates the malignant biological behaviors of glioblastoma cells via enhancing the stability of Linc-00313. Cell Death Dis. 2019;10(9):629.
   PubMedGoogle Scholar
• Nayak S, Aich M, Kumar A, et al. Novel internal regulators and candidate miRNAs within miR-379/miR-656 miRNA cluster can alter cellular phenotype of human glioblastoma. Sci Rep. 2018;8(1):7673.
   PubMedGoogle Scholar
• Chun JN, Cho M, Park S, et al. The conflicting role of E2F1 in prostate cancer: a matter of cell context or interpretational flexibility?, Biochimica et biophysica acta. Rev Cancer. 2020;1873:188336.
   Google Scholar
• Lv BB, Ma RR, Chen X, et al. E2F1-activated SPIN1 promotes tumor growth via a MDM2-p21-E2F1 feedback loop in gastric cancer. Mol Oncol. 2020;14(10):2629–2645.
   PubMed Web of Science ®Google Scholar
• Gong M, Liu H, Sun N, et al. Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo. Nanomedicine (Lond). 2020;15(7):711–723.
   PubMed Web of Science ®Google Scholar
• Chen W, Yang Y, Chen B, et al. MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol. 2014;120(1):43–53.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Han J, Chen Q. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol. 2015;8:12698–12707.
   PubMed Web of Science ®Google Scholar
• Shou J, Gao H, Cheng S, et al. LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis. Cancer Cell Int. 2021;21(1):39.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhu Y, Zhao M, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One. 2013;8(8):e70192.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu Q, Li Z, et al. LncRNA LINC00319 is associated with tumorigenesis and poor prognosis in glioma. Eur J Pharmacol. 2019;861:172556.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. Bioengineered. 2020;11(1):91–102.
   PubMed Web of Science ®Google Scholar
• Liu H, Song M, Sun X, et al. T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways. Bioengineered. 2021;12(1):565–577.
   PubMed Web of Science ®Google Scholar
• Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011;17(9):3029–3038.
   PubMed Web of Science ®Google Scholar
• Yang L, Li N, Yan Z, et al. MiR-29a-mediated cd133 expression contributes to cisplatin resistance in CD133(+) glioblastoma stem cells. J Mol Neurosci. 2018;66(3):369–377.
   PubMed Web of Science ®Google Scholar
• Guo Y, Yan K, Fang J, et al. Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res. 2013;32(1):41.
   PubMedGoogle Scholar
• Yin J, Shen X, Li M, et al. miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1. Oncol Lett. 2018;16:3587–3592.
   PubMed Web of Science ®Google Scholar
• Cataldo A, Romero-Cordoba S, Plantamura I, et al. MiR-302b as a combinatorial therapeutic approach to improve cisplatin chemotherapy efficacy in human triple-negative breast cancer. Cancers (Basel). 2020;12(8):2261.
   Web of Science ®Google Scholar
• Shu HK, Julin CM, Furman F, et al. Overexpression of E2F1 in glioma-derived cell lines induces a p53-independent apoptosis that is further enhanced by ionizing radiation. Neuro Oncol. 2000;2(1):16–21.
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Lemoine MG, Hu M, et al. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol. 2001;19:359–365.
   PubMed Web of Science ®Google Scholar